The financialization of big pharma

Abstract

In this article, we employ a Veblenian framework to analyze three dimensions of corporate financialization: the expansion of the balance sheet, the rising importance of intangible assets and the growing levels of financial payouts. Our focus is the pharmaceutical sector, which is strongly dominated by a handful of large corporations known as Big Pharma. In our empirical analysis of the financial accounts of 27 of the largest global pharmaceutical corporations for the years 2000–2018, we find evidence of a shift in Big Pharma’s business model from one focused on productive capacity (reflected by fixed capital and R&D) to one focused on intangible assets (reflected by patents, brands and goodwill). The modus operandi of Big Pharma is one which increasingly resembles that of a private equity fund which generates returns for shareholders that are supported by monopolized knowledge through intellectual property rights, capitalized future earnings potential and rising debt burdens. Our framework facilitates the study of the different elements of financialization and how they do (or do not) co-evolve over time, within and between industries, and between countries or global regions.